Can MRK's Ongoing M&A Push Aid Long-Term Growth Ahead of Keytruda LOE?

Key Takeaways Merck (MRK) has been actively pursuing mergers and acquisitions (M&A) to strengthen its pipeline and sustain long-term growth, particularly in oncology and immunology. The company's recent deals reflect a strategy to diversify its broader portfolio and secure next-generation therapies, while maintaining competitive leadership. Earlier this week, Merck announced a definitive agreement to acquire California-based cancer biotech, Terns Pharmaceuticals (TERN) , for $53.00 per share in cash, a tota ...